GlobeNewswire Inc | Nov 10, 2021 06:30AM EST

November 10, 2021

WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced participation in the following upcoming investor conferences:

-- Stifel 2021 Virtual Healthcare Conference: Management will participate in a fireside chat discussion on Tuesday, November 16, 2021, at 8:40 a.m. ET. -- Jefferies 2021 Virtual London Healthcare Conference: Management will participate in a fireside chat discussion during the conference, being held November 16-19, 2021. The fireside chat will be available to registered participants on-demand between 8:00 a.m. GMT on November 18, 2021, and 5:00 p.m. GMT on November 19, 2021. -- Evercore ISI 4th Annual HealthconX Conference: Management will participate in a fireside chat discussion on Wednesday, December 1, 2021, at 2:40 p.m. ET.

The webcasts will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 60 days following the presentations.

About Adagio TherapeuticsAdagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The companys portfolio of antibodies has been optimized using Adimabs industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagios portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Contacts:Media Contact:Dan Budwick, 1ABDan@1abmedia.com

Investor Contact:Monique Allaire, THRUST Strategic Communicationsmonique@thrustsc.com